Gilad Preminger

Senior Product Marketing Manager at Vectorious Medical Technologies

Gilad Preminger has extensive work experience primarily in product marketing and business development roles. Gilad is currently working as a Senior Product Marketing Manager at Vectorious Medical Technologies since 2023. Prior to this, they worked as a Product Marketing Manager at SolarEdge Technologies from 2021 to 2023. From 2015 to 2020, they served as a Product Marketing Manager at Ribbon Communications. Before that, they worked as a Marketing & Business Development consultant from 2013 to 2015. Gilad also has experience as a Director of Products and Services Marketing at Cellcom from 2004 to 2013, as a VP Marketing & Sales at Med-1 from 2001 to 2004, as a Director of Marketing at Barak 013 (now Cellcom) from 1999 to 2001, as a Products & Services Marketing Manager at Pelephone from 1997 to 1999, and as a Senior Project Manager at P.o.c Strategic and Marketing Consulting from 1994 to 1997.

Gilad Preminger completed their Bachelor of Science (BSc) degree in Industrial Engineering at Tel Aviv University from 1990 to 1994. Gilad then pursued a Master of Business Administration (MBA) degree with a focus on Marketing and Finance from Tel Aviv University, which they completed from 1995 to 1997.

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Vectorious Medical Technologies

1 followers

Vectorious Medical Technologies developed the V-LAP, the worlds first in-heart microcomputer which enables optimal treatment for heart failure patients, increasing their quality of life and life expectancy.The V-LAP sensory implant is the first digital, wireless, battery-less device that is able to communicate from deep within the body. Itmonitors the heart’s left atrium pressure (LAP) which has been proven to be the earliest, most accurate and effective predictor for heart failure deterioration.Vectorious is actively conducting clinical studies in Europe (Italy, Germany, UK and Israel) for the purpose of obtaining a CE mark. It is expected to launch a clinical study in the US in 2020.


Headquarters

Tel Aviv, Israel

Employees

11-50

Links